Asia Pacific Infectious Disease Immunoassay Testing Market - Size, Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - Request a Free Sample

Asia Pacific Infectious Disease Immunoassay Testing Market Overview

The Asia Pacific infectious disease immunoassay testing market reached a value of approximately USD 2.10 Billion in 2025. The market is expanding due to rising infection rates, wider screening programs, and improving laboratory infrastructure. Hospitals and diagnostic centers are adopting automated analyzers, rapid tests, and multiplex assays for earlier detection. Growth is also supported by public health initiatives, higher healthcare spending, and increasing awareness of timely diagnosis. China, India, Japan, South Korea, and Southeast Asia remain important markets for future demand growth.

Asia Pacific Infectious Disease Immunoassay Testing Market Growth Analysis and Key Influencers

Asia Pacific Infectious Disease Immunoassay Testing Market Dynamics

This section analyzes factors influencing the market, including disease incidence, diagnostic innovation, screening programs, regulatory requirements, laboratory capacity, pricing pressure, healthcare investment, and access to advanced testing across Asia Pacific.

Asia Pacific Infectious Disease Immunoassay Testing Market Growth Drivers

Multiplex Respiratory Approvals Strengthen Asia Pacific Diagnostic Testing Market Development

Rising respiratory infection screening and growing demand for convenient multiplex testing are expanding diagnostic access across Asia Pacific. For instance, in March 2026, Australia’s TGA approved CorePharma’s self-test for SARS-CoV-2, RSV, adenovirus, and influenza A and B, using a single antigen kit. This approval may support market growth by widening home-based detection, reducing separate testing requirements, improving early case identification, and encouraging suppliers to introduce broader rapid immunoassay portfolios across regional healthcare systems and community settings.

Asia Pacific Infectious Disease Immunoassay Testing Market Restraints

Performance Concerns Restrict Asia Pacific Infectious Disease Testing Market Development

Greater reliance on self-testing and rising demand for rapid sexually transmitted infection detection are increasing regulatory scrutiny across Asia Pacific. For instance, in July 2026, Australia’s TGA reported false-negative concerns with the TouchBio chlamydia and gonorrhea self-test and suspended it from lawful supply. During the forecast period, these market restraints may increase validation costs, strengthen post-market monitoring requirements, delay product launches, and encourage laboratories and patients to rely on confirmatory testing before clinical decisions are made safely across the region.

Asia Pacific Infectious Disease Immunoassay Testing Market Opportunities

Technology Transfer Expands Asia Pacific Immunoassay Commercialization and Market Avenues

High lymphatic filariasis burden and increasing support for locally manufactured diagnostics are encouraging public-private collaboration across Asia Pacific. For instance, in May 2026, India’s ICMR invited companies to license, develop, manufacture, and commercialize a novel immunoassay for screening infective and infected stages of lymphatic filariasis. During the forecast period, these market opportunities may expand affordable testing, strengthen domestic production, improve disease surveillance, and support wider distribution of specialized assays in endemic communities with limited access to centralized laboratories and clinics.

Asia Pacific Infectious Disease Immunoassay Testing Market Trends

Regional Partnerships Advance Asia Pacific Automated Immunoassay Testing Bolstering Market Collaboration

Growing laboratory automation and demand for highly sensitive infectious disease testing are encouraging regional technology partnerships. For instance, in May 2025, India-based Agappe Diagnostics and Japan-based Fujirebio advanced their collaboration around Mispa CLEIA immunoassay analyzers and biomarker development, including infectious disease applications. During the forecast period, these market trends may increase adoption of automated chemiluminescent systems, encourage local manufacturing, reduce dependence on imported platforms, and broaden access to high-throughput testing across regional hospitals, clinics, and diagnostic laboratories throughout Asia Pacific.

Asia Pacific Infectious Disease Immunoassay Testing Market Share

Reagents, Kits, and Consumables Likely to Dominate Product Market Share

Reagents, kits, and consumables accounted for 58% of the market during the historical period, supported by recurring laboratory demand, frequent assay use, and continuous replacement requirements. The reagents, kits, and consumables segment is likely to dominate during the forecast period as hospitals and laboratories expand infectious disease testing volumes. Growing adoption of automated platforms, broader screening programs, and the need for reliable assay performance are expected to sustain purchasing activity across healthcare systems throughout Asia Pacific over the coming years.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - Request a Free Sample

Asia Pacific Infectious Disease Immunoassay Testing Market Analysis by Region

China accounted for 35% of the market during the historical period, supported by its large population, extensive hospital network, and expanding diagnostic manufacturing base. The China segment is likely to lead during the forecast period as healthcare investment, infectious disease surveillance, and laboratory modernization continue to increase. Rising demand for automated testing, wider access to hospital services, and stronger domestic production of assays and analyzers are expected to reinforce the country’s position within the Asia Pacific market over coming years.

Leading Players in the Asia Pacific Infectious Disease Immunoassay Testing Market

Asia Pacific Infectious Disease Immunoassay Testing Market Segmentation

Key Questions Answered in the Asia Pacific Infectious Disease Immunoassay Testing Market Report

• What was the Asia Pacific infectious disease immunoassay testing market value in 2025?
• What is the Asia Pacific infectious disease immunoassay testing market forecast outlook for 2026-2035?
• What major factors aid the demand for the Asia Pacific infectious disease immunoassay testing market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major Asia Pacific infectious disease immunoassay testing market trends?
• Which product and service segment is expected to dominate the market?
• Which type of testing segment is expected to hold the largest market share?
• Which sample type is expected to account for the highest market share?
• Which disease type is expected to account for the highest market share?
• Which technology is expected to account for the highest market share?
• Which application is expected to account for the highest market share?
• Which end user is expected to account for the highest market share?
• Who are the key players in the Asia Pacific infectious disease immunoassay testing market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: Interviews with diagnostic manufacturers, laboratory managers, microbiologists, clinicians, regulatory specialists, and professionals involved in infectious disease immunoassay testing across Asia Pacific.
• Secondary Research: Sources included company announcements, CE-marking updates, technical documents, MedTech Asia Pacific publications, regulatory reports, scientific journals, and peer-reviewed studies on testing.
• Validation: All quantitative estimates are triangulated using top-down and bottom-up market modeling, validated through expert feedback loops.